Fas expression by tumor stroma is required for cancer eradication (Q36598412)

15 August 2017

Fas expression by tumor stroma is required for cancer eradication (English)

1 reference

15 August 2017

Christoph Loddenkemper

8

object named as

Christoph Loddenkemper

0 references

Karin Schmidt

object named as

Karin Schmidt

6

0 references

author name string

Joanna J Listopad

1

1 reference

15 August 2017

Thomas Kammertoens

2

1 reference

15 August 2017

Kathleen Anders

3

1 reference

15 August 2017

Bjoern Silkenstedt

4

1 reference

15 August 2017

Gerald Willimsky

5

1 reference

15 August 2017

Anja A Kuehl

7

1 reference

15 August 2017

Thomas Blankenstein

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

22 January 2013

1 reference

Proceedings of the National Academy of Sciences of the United States of America

15 August 2017

1 reference

15 August 2017

110

1 reference

15 August 2017

6

1 reference

15 August 2017

2276-2281

1 reference

A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

CD95 promotes tumour growth

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Antigen presented by tumors in vivo determines the nature of CD8 T-cell cytotoxicity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Cancer. Addiction to oncogenes--the Achilles heal of cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Loss of tumor-specific and idiotype-specific immunity with age

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Phase I study of adoptive T-cell therapy using antigen-specific CD8 T cells for the treatment of patients with metastatic melanoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

CD95-dependent bystander lysis caused by CD4 T helper 1 effectors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8 T cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

Bystander elimination of antigen loss variants in established tumors

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8 T cell effector function in SV40 T antigen transgenic mice

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

CD4 T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3568383

A cancer immunosurveillance controversy

20 September 2018

1 reference

12 December 2020

1 reference

12 December 2020

Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells

1 reference

12 December 2020

Cutting Edge: CD8 Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells

1 reference

12 December 2020

Age, thymopoiesis, and CD4 T-lymphocyte regeneration after intensive chemotherapy

1 reference

12 December 2020

Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1218295110

1 reference

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

23341634

1 reference